Five Things Facing Teva’s New CEO Richard Francis
Former Sandoz Head To Take Charge At Teva On 1 January 2023
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.
You may also be interested in...
In just under six weeks Teva will have a new president and CEO, after former Sandoz chief Richard Francis was announced as Kåre Schultz’s replacement from the start of 2023.
Teva maintains that the clinical data package looks sounds for it and partner MedinCell’s proposed 505(b)(2) hybrid risperidone long-acting injectable product, as the firms look to muscle in on the multi-billion-dollar LAI schizophrenia market next year.
Teva is on the hook to pay more than $300m to New York state over the next 18 years, in addition to $210m in damages already agreed under its proposed nationwide settlement deal, after settling claims with the New York Attorney General.